S&P 500   3,843.72 (+0.05%)
DOW   31,625.50 (+0.41%)
QQQ   309.24 (+0.18%)
AAPL   119.58 (-1.52%)
MSFT   231.08 (-0.22%)
FB   264.56 (+0.11%)
GOOGL   2,095.96 (-0.05%)
TSLA   618.48 (+3.43%)
AMZN   3,056.96 (+1.88%)
NVDA   494.29 (-0.84%)
BABA   230.39 (-1.50%)
CGC   31.60 (+1.38%)
GE   13.91 (+2.28%)
MU   89.32 (+0.44%)
NIO   39.18 (+2.81%)
AMD   78.67 (+0.19%)
T   29.51 (-0.37%)
F   12.51 (+1.96%)
ACB   9.58 (-0.21%)
DIS   196.79 (+3.58%)
BA   227.20 (+1.78%)
NFLX   516.85 (+0.09%)
PFE   34.43 (+0.12%)
S&P 500   3,843.72 (+0.05%)
DOW   31,625.50 (+0.41%)
QQQ   309.24 (+0.18%)
AAPL   119.58 (-1.52%)
MSFT   231.08 (-0.22%)
FB   264.56 (+0.11%)
GOOGL   2,095.96 (-0.05%)
TSLA   618.48 (+3.43%)
AMZN   3,056.96 (+1.88%)
NVDA   494.29 (-0.84%)
BABA   230.39 (-1.50%)
CGC   31.60 (+1.38%)
GE   13.91 (+2.28%)
MU   89.32 (+0.44%)
NIO   39.18 (+2.81%)
AMD   78.67 (+0.19%)
T   29.51 (-0.37%)
F   12.51 (+1.96%)
ACB   9.58 (-0.21%)
DIS   196.79 (+3.58%)
BA   227.20 (+1.78%)
NFLX   516.85 (+0.09%)
PFE   34.43 (+0.12%)
S&P 500   3,843.72 (+0.05%)
DOW   31,625.50 (+0.41%)
QQQ   309.24 (+0.18%)
AAPL   119.58 (-1.52%)
MSFT   231.08 (-0.22%)
FB   264.56 (+0.11%)
GOOGL   2,095.96 (-0.05%)
TSLA   618.48 (+3.43%)
AMZN   3,056.96 (+1.88%)
NVDA   494.29 (-0.84%)
BABA   230.39 (-1.50%)
CGC   31.60 (+1.38%)
GE   13.91 (+2.28%)
MU   89.32 (+0.44%)
NIO   39.18 (+2.81%)
AMD   78.67 (+0.19%)
T   29.51 (-0.37%)
F   12.51 (+1.96%)
ACB   9.58 (-0.21%)
DIS   196.79 (+3.58%)
BA   227.20 (+1.78%)
NFLX   516.85 (+0.09%)
PFE   34.43 (+0.12%)
S&P 500   3,843.72 (+0.05%)
DOW   31,625.50 (+0.41%)
QQQ   309.24 (+0.18%)
AAPL   119.58 (-1.52%)
MSFT   231.08 (-0.22%)
FB   264.56 (+0.11%)
GOOGL   2,095.96 (-0.05%)
TSLA   618.48 (+3.43%)
AMZN   3,056.96 (+1.88%)
NVDA   494.29 (-0.84%)
BABA   230.39 (-1.50%)
CGC   31.60 (+1.38%)
GE   13.91 (+2.28%)
MU   89.32 (+0.44%)
NIO   39.18 (+2.81%)
AMD   78.67 (+0.19%)
T   29.51 (-0.37%)
F   12.51 (+1.96%)
ACB   9.58 (-0.21%)
DIS   196.79 (+3.58%)
BA   227.20 (+1.78%)
NFLX   516.85 (+0.09%)
PFE   34.43 (+0.12%)
Log in
NASDAQ:NVIV

InVivo Therapeutics Stock Forecast, Price & News

$1.03
-0.06 (-5.05 %)
(As of 03/8/2021 09:44 AM ET)
Add
Compare
Today's Range
$0.97
Now: $1.04
$1.05
50-Day Range
$0.87
MA: $1.34
$1.78
52-Week Range
$0.50
Now: $1.04
$2.69
Volume12,674 shs
Average Volume6.16 million shs
Market Capitalization$21.91 million
P/E RatioN/A
Dividend YieldN/A
Beta1.9
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. The company is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for the implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
InVivo Therapeutics logo

Headlines

InVivo Therapeutics Holdings
November 25, 2020 |  fool.com
10-Q: INVIVO THERAPEUTICS HOLDINGS CORP.
May 15, 2020 |  www.marketwatch.com
InVivo Therapeutics Holdings Corp.
March 31, 2020 |  www.barrons.com
InVivo down 56% after pricing equity offering
March 6, 2020 |  seekingalpha.com
InVivo Therapeutics Holdings Corp
February 16, 2020 |  www.bloomberg.com
InVivo to reverse split shares 1:30
February 3, 2020 |  seekingalpha.com
InVivo Therapeutics Announces Reverse Stock Split
February 3, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVIV
CUSIPN/A
Phone(617) 863-5500
Employees6
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$10.15 per share

Profitability

Net Income$-11,830,000.00

Miscellaneous

Market Cap$21.91 million
Next Earnings Date3/11/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

0.69 out of 5 stars

Medical Sector

1252nd out of 1,968 stocks

Surgical & Medical Instruments Industry

113th out of 169 stocks

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$1.03
-0.06 (-5.05 %)
(As of 03/8/2021 09:44 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVIV News and Ratings via Email

Sign-up to receive the latest news and ratings for NVIV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











InVivo Therapeutics (NASDAQ:NVIV) Frequently Asked Questions

What stocks does MarketBeat like better than InVivo Therapeutics?

Wall Street analysts have given InVivo Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but InVivo Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting InVivo Therapeutics?

InVivo Therapeutics saw a increase in short interest in January. As of January 29th, there was short interest totaling 3,870,000 shares, an increase of 149.7% from the January 14th total of 1,550,000 shares. Based on an average daily volume of 4,990,000 shares, the days-to-cover ratio is currently 0.8 days.
View InVivo Therapeutics' Short Interest
.

When is InVivo Therapeutics' next earnings date?

InVivo Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for InVivo Therapeutics
.

How were InVivo Therapeutics' earnings last quarter?

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) released its earnings results on Wednesday, May, 13th. The biotechnology company reported ($2.47) earnings per share for the quarter.
View InVivo Therapeutics' earnings history
.

How has InVivo Therapeutics' stock been impacted by COVID-19?

InVivo Therapeutics' stock was trading at $1.60 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NVIV stock has decreased by 36.3% and is now trading at $1.02.
View which stocks have been most impacted by COVID-19
.

When did InVivo Therapeutics' stock split? How did InVivo Therapeutics' stock split work?

InVivo Therapeutics's stock reverse split on Wednesday, February 12th 2020. The 1-30 reverse split was announced on Monday, February 3rd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 11th 2020. An investor that had 100 shares of InVivo Therapeutics stock prior to the reverse split would have 3 shares after the split.

Who are InVivo Therapeutics' key executives?

InVivo Therapeutics' management team includes the following people:
  • Dr. Richard M. Toselli, Pres, CEO, Chief Medical Officer & Director (Age 63, Pay $1.22M)
  • Mr. Richard C. Christopher, CFO & Treasurer (Age 51, Pay $553.07k)
  • Dr. Robert S. Langer Jr., Co-Founder & Member of Scientific Advisory Board (Age 72)
  • Dr. Joseph Philip Vacanti, Co-Founder (Age 72)
  • Mr. William D'Agostino PE, Sr. VP of Operations
  • Ms. Heather Hamel, VP of Legal Affairs & Bus. Devel. and Corp. Sec.
  • Dr. Louis Vaickus, Consultant (Age 68)

Who are some of InVivo Therapeutics' key competitors?

What other stocks do shareholders of InVivo Therapeutics own?

What is InVivo Therapeutics' stock symbol?

InVivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV."

Who are InVivo Therapeutics' major shareholders?

InVivo Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.53%).
View institutional ownership trends for InVivo Therapeutics
.

Which major investors are buying InVivo Therapeutics stock?

NVIV stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
View insider buying and selling activity for InVivo Therapeutics
or or view top insider-buying stocks.

How do I buy shares of InVivo Therapeutics?

Shares of NVIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is InVivo Therapeutics' stock price today?

One share of NVIV stock can currently be purchased for approximately $1.02.

How much money does InVivo Therapeutics make?

InVivo Therapeutics has a market capitalization of $21.60 million.

How many employees does InVivo Therapeutics have?

InVivo Therapeutics employs 6 workers across the globe.

What is InVivo Therapeutics' official website?

The official website for InVivo Therapeutics is www.invivotherapeutics.com.

Where are InVivo Therapeutics' headquarters?

InVivo Therapeutics is headquartered at ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139.

How can I contact InVivo Therapeutics?

InVivo Therapeutics' mailing address is ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at (617) 863-5500 or via email at [email protected]


This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.